This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

University Of Maryland Breast Cancer Research Pioneer Dr. Angela Brodie Appointed Fellow Of New American Association For Cancer Research Academy

Dr. Brodie Best Known for Role in Developing Aromatase Inhibitors

BALTIMORE, March 28, 2013 /PRNewswire-USNewswire/ -- Angela H. Brodie, Ph.D., a University of Maryland scientist whose research paved the way for a new class of drugs widely used to treat breast cancer patients around the world, has been selected by the American Association for Cancer Research (AACR) as a fellow of the newly created AACR Academy.

Dr. Brodie, professor of pharmacology at the University of Maryland School of Medicine and scientist at the University of Maryland Marlene and Stewart Greenebaum Cancer Center, is one of 106 fellows who will be inducted into the AACR Academy on April 5, 2013, at a ceremony in Washington, D.C. AACR said it created the academy "to recognize and honor distinguished scientists whose major scientific contributions have propelled significant innovation and progress against cancer."

The inaugural class of scientists was selected through a rigorous peer review process. According to AACR, the number of fellows in the class symbolizes the age of the Philadelphia-based professional organization dedicated to advancing cancer research, which was founded in 1907.

"Our Board of Directors made the decision to establish the AACR Academy as a mechanism for recognizing scientists whose contributions to the cancer field have had an extraordinary impact," says Margaret Foti, Ph.D., M.D. (h.c.), AACR's chief executive officer. "Membership in the Fellows of the AACR Academy will be the most prestigious honor bestowed by the American Association for Cancer Research."

Dr. Brodie's research laid the groundwork for a class of drugs called aromatase inhibitors, which help to prevent recurrence of breast cancer in postmenopausal women by reducing estrogen produced by the body, thereby cutting off fuel to the cancer cells. The drugs inhibit the production of aromatase, an enzyme that plays a key role in the biosynthesis of estrogen.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs